These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 30632632)
1. Inhibition of angiogenesis and tumor growth by a novel 1,4-naphthoquinone derivative. Murota H; Shinya T; Nishiuchi A; Sakanaka M; Toda KI; Ogata T; Hayama N; Kimachi T; Takahashi S Drug Dev Res; 2019 May; 80(3):395-402. PubMed ID: 30632632 [TBL] [Abstract][Full Text] [Related]
2. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. Lai L; Liu J; Zhai D; Lin Q; He L; Dong Y; Zhang J; Lu B; Chen Y; Yi Z; Liu M Br J Pharmacol; 2012 Feb; 165(4b):1084-96. PubMed ID: 21658027 [TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma. Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924 [TBL] [Abstract][Full Text] [Related]
4. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling. Ma Q; Chen W; Chen W Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645 [TBL] [Abstract][Full Text] [Related]
5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Huang SW; Lien JC; Kuo SC; Huang TF Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611 [TBL] [Abstract][Full Text] [Related]
7. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis. Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891 [TBL] [Abstract][Full Text] [Related]
8. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling. Huang SW; Lien JC; Kuo SC; Huang TF Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Kimura Y; Sumiyoshi M; Baba K Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells. Wang LL; Li JJ; Zheng ZB; Liu HY; Du GJ; Li S Eur J Pharmacol; 2004 Oct; 502(1-2):1-10. PubMed ID: 15464084 [TBL] [Abstract][Full Text] [Related]
11. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720 [TBL] [Abstract][Full Text] [Related]
12. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells. Wei Y; Yang Q; Zhang Y; Zhao T; Liu X; Zhong J; Ma J; Chen Y; Zhao C; Li J Oncotarget; 2017 Feb; 8(9):15230-15241. PubMed ID: 28122355 [TBL] [Abstract][Full Text] [Related]
13. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081 [TBL] [Abstract][Full Text] [Related]
14. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. Zhu BH; Zhan WH; Li ZR; Wang Z; He YL; Peng JS; Cai SR; Ma JP; Zhang CH World J Gastroenterol; 2007 Feb; 13(8):1162-9. PubMed ID: 17451194 [TBL] [Abstract][Full Text] [Related]
15. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis. Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327 [TBL] [Abstract][Full Text] [Related]
16. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074 [TBL] [Abstract][Full Text] [Related]